Phenolic Acid Cationic Lipids for mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery systems for nucleic acids, such as liposome-encapsulated mRNA, face challenges in efficiently and safely delivering therapeutic agents to target cells and tissues due to stability issues and toxicity concerns, particularly in achieving effective encapsulation and release of nucleic acids in vivo.
Innovation Solution
Development of a novel class of cationic lipid compounds synthesized from phenolic acids, which form lipid nanoparticles capable of high encapsulation efficiency and biodegradability, incorporating cleavable groups like esters and disulphides to enhance biocompatibility and pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional cationic lipids are used for nucleic acid delivery, then encapsulation efficiency is improved, but toxicity increases
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by introducing cleavable groups (esters, disulphides) and varying chain lengths and compositions. This changes the physical and chemical parameters of the lipids to achieve high encapsulation efficiency while reducing toxicity through controlled degradation in biological environments.
Solution Approach 2:
The invention creates composite lipid structures combining cationic head groups with cleavable linkages and hydrophobic tails. These composite molecules integrate multiple functions: efficient nucleic acid binding, cellular membrane fusion, and controlled biodegradation, thereby resolving the contradiction between encapsulation efficiency and toxicity.
2Reliability
If cationic lipids are synthesized for in vivo delivery, then delivery effectiveness is improved, but formation of toxic by-products occurs
Solution Approach 1:
The synthesis approach uses modified chemical parameters including cleavable ester and disulphide bonds in the lipid structure. These parameter changes enable the lipids to degrade into non-toxic components in vivo, maintaining delivery effectiveness while eliminating persistent toxic by-products associated with conventional cationic lipids.
Solution Approach 2:
The patent converts the potential harm of stable cationic lipids (which persist and cause toxicity) into a benefit by introducing biodegradable linkages. The stability needed for effective delivery is maintained during circulation, while the cleavable groups ensure safe degradation after delivery, transforming the harmful persistence into a beneficial controlled degradation profile.
3Ease of manufacture
If phenolic acids are used as starting reagents, then synthesis cost and complexity are reduced, but encapsulation efficiency must be maintained
Solution Approach 1:
The patent optimizes the molecular parameters of phenolic acid derivatives, including hydroxyl group positioning, chain length, and cationic head group composition. These parameter adjustments ensure that despite using simple, inexpensive phenolic acid starting materials, the final lipids achieve high encapsulation efficiency comparable to complex conventional cationic lipids.
Solution Approach 2:
The invention employs inexpensive phenolic acid-based lipid structures that are designed to be biodegradable. These disposable-like molecules perform their delivery function effectively and then degrade into harmless products, achieving both economic advantage through simple synthesis from abundant phenolic acids and functional effectiveness through optimized molecular design.
Data Source
AI summary
The present invention provides, in part, phenolic acid lipid compounds of Formula (I), and sub-formulas thereof, or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly canbe useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.